By The Hill |
December 02, 2019
President Trump’s proposal to import cheaper prescription drugs from Canada faces significant headwinds from U.S. pharmaceutical companies and the Canadian government.
Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders.
One of the most important elements of a company’s success is also one of the least tangible —culture.